Thrivent Financial for Lutherans Acquires 65,180 Shares of Xencor, Inc. (NASDAQ:XNCR)

Thrivent Financial for Lutherans increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 127.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,369 shares of the biopharmaceutical company's stock after buying an additional 65,180 shares during the period. Thrivent Financial for Lutherans owned 0.17% of Xencor worth $2,340,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Linden Thomas Advisory Services LLC grew its position in shares of Xencor by 1.6% in the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company's stock valued at $826,000 after purchasing an additional 699 shares during the last quarter. Baillie Gifford & Co. lifted its position in Xencor by 3.3% in the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock worth $445,000 after purchasing an additional 744 shares during the period. Louisiana State Employees Retirement System boosted its stake in Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 900 shares in the last quarter. Diversified Trust Co increased its holdings in Xencor by 7.8% in the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 1,017 shares during the period. Finally, KBC Group NV raised its stake in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 1,213 shares in the last quarter.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 68,684 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the transaction, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bassil I. Dahiyat sold 49,278 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $24.07, for a total value of $1,186,121.46. Following the completion of the transaction, the chief executive officer now owns 352,615 shares of the company's stock, valued at $8,487,443.05. The trade was a 12.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 121,328 shares of company stock valued at $2,879,673. 5.23% of the stock is currently owned by insiders.

Xencor Price Performance

Xencor stock traded up $0.32 during mid-day trading on Thursday, reaching $25.62. 369,070 shares of the company were exchanged, compared to its average volume of 663,341. The company has a fifty day simple moving average of $21.75 and a 200-day simple moving average of $20.44. The firm has a market cap of $1.79 billion, a PE ratio of -8.01 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $26.84.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same quarter last year, the business posted ($0.40) EPS. The firm's revenue for the quarter was down 81.9% on a year-over-year basis. As a group, equities research analysts expect that Xencor, Inc. will post -3.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on XNCR. BMO Capital Markets reaffirmed an "outperform" rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a report on Friday, November 8th. JPMorgan Chase & Co. lifted their price objective on Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Wedbush reaffirmed an "outperform" rating and issued a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. Finally, Royal Bank of Canada increased their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Xencor presently has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.